Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22940138 | 1.00 | ALDH1A1 (0.30) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL77327 | 0.95 | — | — | |
| SCHEMBL25148114 | 0.89 | MEN1 (0.35) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL871278 | 0.89 | MEN1 (0.35) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL4952330 | 0.87 | CES2 (0.32) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL25239237 | 0.82 | CES2 (0.39) | — | |
| SCHEMBL25208334 | 0.82 | CES2 (0.39) | — | |
| SCHEMBL21331525 | 0.81 | CES2 (0.38) | — | |
| SCHEMBL3729335 | 0.80 | HSD17B10 (0.38) | ALDH1A1TP53TSHRHIF1AHSD17B10 | |
| SCHEMBL7262941 | 0.80 | HSD17B10 (0.38) | ALDH1A1TP53TSHRHIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174299-B | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligand and methods of use | 百济神州有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-114174299-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | YALE UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3765026-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | Yale University (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2019177902-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | YALE UNIVERSITY (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | YALE UNIVERSITY | 2019-09-12 | — | — | US | disclosed |
| WO-2017046036-A1 | COMPOUNDS FOR THE MODULATION OF RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046036-A1 | COMPOUNDS FOR THE MODULATION OF RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2008075152-A1 | 1- [4- (SULFONYL) -PHENYL] -5- (BENZYL) -IH-I, 2, 4-TRIAZOL DERIVATIVES AS INHIBITORS OF CARBONIC ANHYDRASE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075152-A1 | 1- [4- (SULFONYL) -PHENYL] -5- (BENZYL) -IH-I, 2, 4-TRIAZOL DERIVATIVES AS INHIBITORS OF CARBONIC ANHYDRASE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | ALDH1A1 4291/4885TP53 228/4885TSHR 4036/4885 |
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | BTK, CBL, CRBN | ALDH1A1 4291/4885TP53 228/4885TSHR 4036/4885 |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | ALDH1A1 4291/4885TP53 228/4885TSHR 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.